Cabergoline
Caber · Dostinex · Cabaser · FCE 21336
Last updated
At a glance
Overview
Why Cabergoline Earns Its Place in the Drawer#
Cabergoline is the sharpest tool available for controlling prolactin — and on 19-nor cycles (nandrolone, trenbolone), a poorly managed prolactin level is the difference between a productive blast and a cycle where libido tanks, nipples get itchy, and erections go soft despite textbook-perfect estradiol. A single 0.5 mg dose drops serum prolactin within hours and keeps it suppressed for a week or longer, which is why twice-weekly (sometimes once-weekly) dosing does the job.
"A single 0.5 mg oral dose of cabergoline induced a significant reduction in serum PRL concentrations within 3 hours, with suppression maintained for at least 7 days." — Andreotti et al., JCEM 1995
Beyond the 19-nor use case, physique-focused users reach for caber to rescue stalled libido in PCT when prolactin is stubbornly elevated, to blunt prolactin creep on high-dose GH protocols, and — off-label, occasionally — to shorten the post-orgasm refractory period. What's shifted over the last few years is the community consensus: caber is no longer a default add-on to every deca or tren cycle. It's a tool you pull when bloodwork or symptoms call for it, because over-suppressed prolactin produces the same sexual dysfunction users are trying to avoid, and chronic low-dose exposure quietly adds up on the one metric that actually matters for long-term safety — cumulative lifetime dose.
This page covers the full protocol: dosing ladders for prophylactic, rescue, and sexual-performance use; how to time bloodwork around caber's 63–68 hour half-life; how it stacks with SERMs in PCT and with AIs mid-cycle; how to manage the nausea and orthostatic hypotension that hit in week one; where the cardiac-valve signal actually lives on the dose-response curve; and where pramipexole, P5P, or simply fixing your estradiol will serve you better than reaching for caber at all.
How Cabergoline works
Cabergoline is a long-acting ergoline derivative that works by hijacking the brain's dopamine signalling to shut down prolactin release at the pituitary. For physique-focused users, the relevant story is almost entirely about lactotroph suppression — but the secondary receptor activity at serotonin and adrenergic sites is what dictates the side-effect ceiling and the cumulative-dose caution.
D2 Agonism at Pituitary Lactotrophs#
Cabergoline is a potent, highly selective agonist at the dopamine D2 receptor, with much weaker activity at D1, 5-HT1, 5-HT2, and α-adrenergic sites. The clinically relevant action happens in the tuberoinfundibular pathway: D2 receptors on pituitary lactotroph cells, when activated, directly suppress prolactin gene transcription and vesicular release. One oral dose is enough to shut down PRL output for a full week.
"A single 0.5 mg oral dose of cabergoline induced a significant reduction in serum PRL concentrations within 3 hours, with suppression maintained for at least 7 days." — Andreotti AC et al., J Clin Endocrinol Metab (1995)
This is why caber works the way it does in a 19-nor cycle: prolactin elevation driven by the progestogenic activity of nandrolone or trenbolone (puffy/itchy nipples, lactation, libido crash despite adequate test and controlled E2) gets dismantled at the source rather than masked downstream.
Restoration of the Dopamine–GnRH–LH Axis#
Elevated prolactin is not an isolated nuisance — it actively suppresses GnRH pulsatility at the hypothalamus, which blunts LH, which blunts endogenous testosterone. This is the mechanism behind prolactin-driven ED and anorgasmia on deca/tren even when estradiol is dialled in. Pulling prolactin back into range releases the brake on GnRH and restores the dopaminergic tone that drives libido, motivation, and the refractory-period shortening users notice acutely after a dose.
The practical corollary: crashing prolactin below the reference range produces the same sexual dysfunction as having it elevated. More caber is not better. The goal is low-normal, not suppressed.
Long Functional Half-Life and Receptor Occupancy#
Cabergoline's unusual kinetics are what make twice-weekly (or even weekly) dosing viable. Plasma elimination is slow, and the drug binds D2 receptors tightly enough that functional suppression outlasts measurable plasma levels by a wide margin.
"Cabergoline is a long-acting dopamine D2 receptor agonist with a functional plasma elimination half-life of about 63–68 h, which allows for once- or twice-weekly dosing in clinical use." — Del Dotto P, Bonuccelli U., Clin Pharmacokinet (2003)
Two implications the reader should internalize:
| Fact | Consequence |
|---|---|
| ~65 h half-life | Steady state takes ~4 weeks — don't up-titrate weekly chasing PRL numbers |
| 7–28 day PRL suppression per dose | Mon/Thu split is convention, not necessity; weekly works at low doses |
| Food effect: negligible | Take with food anyway to blunt first-dose nausea |
Persiani and colleagues confirmed that food intake has no meaningful impact on PK or tolerability (Persiani et al. 1996), so dosing with a meal before bed is purely a nausea-management choice — not a bioavailability trade-off.
5-HT2B Agonism — The Valvulopathy Mechanism#
The reason cabergoline carries a cumulative-dose ceiling rather than just an acute side-effect profile is its off-target activity at the 5-HT2B serotonin receptor expressed on cardiac valvular fibroblasts. Chronic agonism here drives fibroblast proliferation and valve thickening — the same mechanism that pulled fenfluramine and pergolide from the market. The signal is clear at Parkinson's-range exposure (2–6 mg/day chronically) and measurable, though small, at hyperprolactinemia doses accumulated over years.
"Exposure above 115 mg cumulative cabergoline was associated with increased odds of ≥2 valves with grade 2+ regurgitation (OR, 8.8; 95% CI, 1.0 to 77.0)." — Steffensen C et al., J Clin Endocrinol Metab (2020)
Practical takeaway: a user running 0.5 mg/week across a few cycles per year is nowhere near the 115 mg cumulative threshold. A user running 0.5 mg twice weekly indefinitely as a "just in case" addition across a decade is approaching it. Cumulative dose is the variable to track — not weekly dose.
Dopaminergic CNS Effects#
Because caber crosses the blood-brain barrier and hits D2 receptors in the striatum and mesolimbic system, it produces the expected dopaminergic spectrum: improved libido, sharper motivation, occasional mood lift, and — at chronic higher doses — the Parkinson's-population side effects of impulse-control disorders (hypersexuality, compulsive behaviour, gambling). These are rare at PED doses but documented. The acute libido and refractory-period benefit that users chase with 0.5 mg pre-event dosing is this same CNS dopaminergic action, not the prolactin suppression itself (prolactin doesn't drop fast enough for a 3-hour pre-game dose to work through that pathway alone).
Tie this back to the practical outcome: caber's job in a physique-focused stack is to keep prolactin in range so libido, erections, and nipple tissue behave on 19-nor cycles — and to do so without over-suppressing PRL or stacking cumulative exposure unnecessarily. Everything else it does is either a pleasant side effect (CNS dopamine) or a reason to respect the ceiling (5-HT2B).
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.125–0.25 mg | Twice weekly | Documented entry-level range |
| Mid | 0.25–0.5 mg | Twice weekly | Most commonly studied range |
| High | 0.5–1 mg | Twice weekly | Typically split Mon/Thu. Take with food, before bed — first-dose nausea and orthostatic hypotension are common. Long half-life means steady state takes ~4 weeks; don't chase prolactin weekly. |
Cycle length & outcomes
Documented cycle
2–16 weeks
Plateau after
16 wks
Cycle Length & Onset#
Cabergoline isn't cycled in the AAS sense — it's deployed as a tool alongside the compounds that actually cause prolactin issues (primarily nandrolone, trenbolone, and high-dose GH). Cycle length tracks the offending compound's duration, plus a short tail.
Onset is fast but steady state is slow. A single 0.5 mg dose suppresses prolactin within 3 hours and keeps it down for at least a week:
"A single 0.5 mg oral dose of cabergoline induced a significant reduction in serum PRL concentrations within 3 hours, with suppression maintained for at least 7 days." — Andreotti et al., JCEM 1995
But the 63–68 hour half-life means true steady state takes ~4 weeks:
"Cabergoline is a long-acting dopamine D2 receptor agonist with a functional plasma elimination half-life of about 63–68 h, which allows for once- or twice-weekly dosing in clinical use." — Del Dotto & Bonuccelli, Clin Pharmacokinet 2003
Translation: don't chase prolactin numbers weekly and up-titrate. You'll overshoot and crash PRL, producing the same anorgasmia and ED you were trying to avoid. Set the dose, wait four weeks, then pull labs.
Cabergoline Dosage by Goal#
| Use Case | Cycle Length | Dose |
|---|---|---|
| Prophylactic on moderate 19-nor (deca ≤400mg/wk) | Cycle duration + 2 wks | 0.25 mg once weekly |
| Symptomatic on deca / tren (confirmed ↑PRL) | Until symptoms + labs resolve | 0.25 mg twice weekly |
| Heavy tren or prolactin-driven gyno flare | 2–4 wks rescue | 0.5 mg twice weekly |
| PCT adjunct (PRL blunting recovery) | 4–6 wks | 0.25 mg twice weekly |
| GH cycle adjunct (high-dose GH with PRL creep) | Duration of GH run | 0.25 mg once weekly |
| Sexual performance (refractory period) | Acute, occasional | 0.5 mg, 3–4h pre-event |
Split twice-weekly doses Mon/Thu. Take with food before bed — first-dose nausea and orthostatic hypotension are the two things that sandbag new users, and both are blunted by dosing horizontal. Food doesn't affect absorption:
"Intake of cabergoline with food had no significant effect on its pharmacokinetic profile or tolerability, suggesting that it can be administered without regard to meals." — Persiani et al., Biopharm Drug Dispos 1996
So food is purely a tolerability move, not a PK one.
Cabergoline PCT Protocol#
Cabergoline is not a PCT compound. It does nothing to restart the HPTA, doesn't bind SERM targets, doesn't touch aromatase. Its role in PCT is strictly adjunctive: if libido and erectile function haven't returned 3–4 weeks into a standard SERM-based PCT (clomid / enclomiphene / tamoxifen) and bloodwork shows prolactin still elevated, 0.25 mg twice weekly for 4–6 weeks layered on top of the real PCT can unblock things.
Draw prolactin fasted, morning, not post-workout — exercise transiently spikes PRL and will give you a false positive that convinces you to run caber you don't need.
Tapering & Loading#
No loading phase. No taper required. The long half-life tapers itself — plasma levels decay over ~2 weeks after the last dose. Just stop when the offending compound clears.
The one exception: if you've been running 0.5 mg twice weekly for months and want to drop, step to 0.25 mg twice weekly for 2 weeks before stopping, purely to avoid any rebound hyperprolactinemia overshoot.
Bloodwork Cadence#
- Baseline prolactin before starting any 19-nor or high-dose GH cycle.
- Week 4–6 into the cycle (steady state reached, symptomatic window).
- Mid-PCT if sexual function hasn't normalized.
- Echocardiogram every few years if lifetime cumulative caber approaches 100 mg — the valvulopathy signal is real at exposure levels well above typical PED use, but track it.
"Exposure above 115 mg cumulative cabergoline was associated with increased odds of ≥2 valves with grade 2+ regurgitation (OR, 8.8; 95% CI, 1.0 to 77.0)." — Steffensen et al., JCEM 2020
At 0.5 mg/week on cycles, reaching 115 mg cumulative takes ~4.5 years of continuous dosing. Most users running caber as-needed on a few blasts will never come close — but if you're a perpetual-blaster running prophylactic caber year-round, log your totals.
Cabergoline vs Alternatives#
Pramipexole is the main non-ergot alternative — no 5-HT2B activity, so no valvular concern, but it's rougher on nausea and psych side effects during titration. Dosed 0.25–0.5 mg at bedtime. Useful if you've already banked significant caber exposure or have any cardiac history.
P5P (pyridoxal-5-phosphate) at 200–400 mg/day is the "try this first" option — mild prolactin-lowering effect, cheap, no side effects. Often enough for borderline elevations.
Fixing estradiol first. A lot of "prolactin symptoms" on cycle — puffy nipples, libido dip, soft erections — are actually estrogen issues masquerading as prolactin issues. Caber won't fix estrogenic gyno. Pull a full hormone panel before reaching for caber; the answer is often an AI adjustment, not a D2 agonist.
Run it lean, run it when bloodwork justifies it, and caber is one of the cleanest tools on the shelf for keeping 19-nor cycles functional.
Risks & mistakes
Common (most users)#
Most of what cabergoline throws at you shows up in the first 1–2 weeks and fades as you hit steady state. Dosing with food, right before bed solves most of it.
- Nausea / GI upset — classic first-dose effect. Dose with a real meal, not a snack, and dose at bedtime so you sleep through the peak. If 0.25 mg still wrecks you, split to 0.125 mg twice weekly for the first two weeks.
- Orthostatic hypotension / dizziness — stand up slowly the morning after a dose, especially dose #1. Hydrate, salt normally, and don't stack the first caber dose with a PDE5 inhibitor or a pre-workout on the same day.
- Headache, fatigue, nasal congestion — typically resolve within the first week. Don't chase them with more caffeine; it makes the BP swings worse.
- Vivid dreams / mild insomnia if dosed late — move the dose to dinner rather than right before sleep if dreams are disruptive.
- Transient mood flattening or "wired-tired" feel — dopaminergic adjustment. Usually settles by week 2 at steady state. If it doesn't, your dose is too high — drop it, don't add stimulants.
Uncommon (dose-dependent or individual)#
These are the signs you've gone past what you actually needed. The fix is almost always lower the dose, not add something.
- Crashed prolactin = the exact symptoms you were trying to fix — anorgasmia, ED, low libido, emotional blunting. Prolactin below the reference range produces the same sexual dysfunction as prolactin above it. If libido tanks on caber, pull bloodwork before assuming you need more.
- Persistent low mood, anhedonia, apathy — dopaminergic over-correction. Drop the dose or extend the interval. Check prolactin.
- Impulse-control changes (gambling, hypersexuality, compulsive behaviors) — well-documented in Parkinson's populations at multi-mg daily dosing, rare at PED doses but not zero. If a partner notices before you do, treat it seriously and discontinue.
- Raynaud-like vasospasm, cold fingers/toes, peripheral edema — ergot-class effect. Back off dose; if it persists off-drug, stop and don't re-run.
- Blood pressure instability — usually hypotensive, occasionally the opposite. Check BP in week 1 of any new dose. Bloodwork: basic metabolic panel if symptoms persist.
Rare but serious#
Low-incidence but the reason you respect cumulative exposure rather than treating caber as a free ancillary.
-
Cardiac valvulopathy (mitral / tricuspid / aortic regurgitation) via 5-HT2B agonism on valvular fibroblasts. The clean signal is at Parkinson's-range dosing — the NEJM data came from patients on multi-mg daily doses:
"Exposure to cabergoline was associated with significantly increased risks of moderate-to-severe regurgitation of the mitral, tricuspid, and aortic valves among Parkinson's patients treated at high cumulative doses." — Zanettini et al., NEJM (2007)
At hyperprolactinemia-range doses the signal is much smaller but not zero. The practical threshold physique users should track:
"Exposure above 115 mg cumulative cabergoline was associated with increased odds of ≥2 valves with grade 2+ regurgitation (OR, 8.8; 95% CI, 1.0 to 77.0)." — Steffensen et al., JCEM (2020)
Warning signs: new exertional dyspnea, unexplained fatigue, new murmur on exam, ankle edema. Stop and get an echo.
-
Pleural, pericardial, or retroperitoneal fibrosis — ergot-class effect, rare, reported at chronic high doses. Warning signs: persistent dry cough, pleuritic chest pain, unexplained flank/back pain, unexplained renal function changes. Stop and work it up.
-
Severe hypersensitivity / ergot reaction — rare but definitive reason to never re-dose.
Hard contraindications#
These lines don't get crossed, regardless of how mild your protocol feels:
- Known valvular heart disease (existing moderate-or-worse regurgitation, valve replacement, rheumatic valve history) — pick pramipexole or address prolactin another way.
- History of pulmonary, pericardial, or retroperitoneal fibrotic disorders.
- Uncontrolled hypertension — stabilize BP before starting. Caber's BP effects are unpredictable on top of untreated HTN.
- Ergot alkaloid hypersensitivity — including reactions to ergotamine, methylergonovine, bromocriptine, pergolide.
- Concurrent D2 antagonists — antipsychotics (haloperidol, risperidone, olanzapine, etc.) and metoclopramide directly oppose the drug and the combination is pharmacologically incoherent.
- Pregnancy or near-term conception attempts — discontinue at least 4 weeks before trying to conceive. The 63–68 h half-life means meaningful drug levels persist for weeks after the last dose.
- Other ergot derivatives on board — do not stack with ergotamine, dihydroergotamine, bromocriptine, or methysergide.
Sex-specific and PCT considerations#
Dosing is sex-neutral — women running 19-nors deal with the same prolactin issues and dose identically (0.25 mg twice weekly typical, titrated to bloodwork). The pregnancy washout is the one hard gender-specific rule: if conception is anywhere on the roadmap, stop caber a month out minimum.
On the PCT side, cabergoline is not a PCT compound and doesn't restart the HPTA — that's the SERM's job (enclomiphene, clomid, tamoxifen). Caber is an adjunct you add when post-cycle libido won't return and bloodwork confirms elevated prolactin is part of the picture. If prolactin is normal and libido is still flat, the problem is estradiol, testosterone, or time — not caber. Running it "just to be safe" during PCT adds cumulative exposure for no benefit.
Cumulative exposure is the number to track. A lifter running 0.5 mg/week for 12 weeks a year racks up ~6 mg/year; that's fine for many years. A user on 1 mg/week year-round hits the 115 mg threshold in about two years. Log it, and if you're a long-term user, get a baseline echo and repeat every 2–3 years.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.08 | ×1.00 | ×1.15 | |
| synergistic | ×1.06 | ×1.00 | ×1.13 | |
| synergistic | ×1.12 | ×1.07 | ×1.10 | |
| synergistic | ×1.05 | ×1.02 | ×1.12 | |
| synergistic | ×1.10 | ×1.05 | ×1.07 |
Pharmacokinetic conflicts, competing pathways, or compounded toxicity. Multipliers below 1 indicate the affected axis.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| antagonistic | ×1.00 | ×1.00 | ×0.85 |
FAQ — Cabergoline
Research & citations
5 studies cited on this page.
Conclusion
Cabergoline is a go-to ancillary for prolactin management on 19-nor cycles but best used when symptoms or bloodwork justify it — not as a blanket add-on. It reliably crushes elevated PRL, restores libido, and undoes the sexual sides that tank quality of life on deca or tren.
Key takeaways:
- Typical dose: 0.25–0.5 mg taken twice weekly, split (e.g., Mon/Thu)
- Oral tabs or liquid; take with food before bed to avoid nausea and dizziness
- Effective for prolactin-driven ED, anorgasmia, and nipple sensitivity when PRL is elevated
- Stack with a SERM/AI only if estradiol is also an issue; caber will not fix estrogenic gyno
- Cycle length: 2–16 weeks; most users run for 4–8 weeks only as needed
- Track cumulative exposure — keep total well under 100 mg for minimal valvulopathy risk (Steffensen et al. 2020)
- Not a standalone PCT drug — use as an adjunct when prolactin lingers post-cycle
Dial in with bloodwork, respect side effects, and you can reliably kill prolactin issues without the old-school overkill.